LONN.SW Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 18:31):

Stats
Dzisiejszy wolumen	115 131
Średni wolumen	203 636
Kapitalizacja rynkowa	38.64B
EPS	CHF0 ( 2024-01-25 )
Następna data zysków	( CHF0 ) 2024-07-19
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	34.22
ATR14	CHF0.264 (0.05%)

Wolumen Korelacja

Długi: -0.07 (neutral)

Krótki: -0.10 (neutral)

Signal:(52.974) Neutral

Lonza Group AG Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lonza Group AG Korelacja - Waluta/Towar

0.32
( neutral )

0.56
( weak )

0.33
( neutral )

0.55
( weak )

0.45
( neutral )

-0.20
( neutral )

Lonza Group AG Finanse

Annual	2023
Przychody:	CHF6.72B
Zysk brutto:	CHF1.82B (27.04 %)
EPS:	CHF8.88

FY	2023
Przychody:	CHF6.72B
Zysk brutto:	CHF1.82B (27.04 %)
EPS:	CHF8.88

FY	2022
Przychody:	CHF6.22B
Zysk brutto:	CHF2.30B (36.96 %)
EPS:	CHF16.37

FY	2021
Przychody:	CHF5.41B
Zysk brutto:	CHF2.11B (39.01 %)
EPS:	CHF39.65

Financial Reports:

No articles found.

Lonza Group AG

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.